|
|||||
|
|
The impact of persistence with mirabegron usage vs switching to onabotulinumtoxinA on healthcare costs and resource utilization in patients with overactive bladder in the United States |
|
| Authors: | Daniel Bin Ng Robert Espinosa Scott J Johnson David Walker Katherine Gooch |
| Institution: | 1. Medical Affairs, Americas, Astellas Pharmaceutical Global Development, Northbrook, IL, USA;2. Medicus Economics LLC, Milton, MA, USA |
| Abstract: | |
| Keywords: | Anti-muscarinics β3-adrenoceptor agonists onabotulinumtoxinA overactive bladder |